Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Quarterly results put Current Deferred Revenue at $6.2 million for Q1 2022, down 65.07% from a year ago — trailing twelve months through Mar 2022 was $6.2 million (down 65.07% YoY), and the annual figure for FY2021 was $8.1 million, down 61.0%.

Solid Biosciences has reported Current Deferred Revenue over the past 3 years, most recently at $6.2 million for Q1 2022.

  • Current Deferred Revenue reached $6.2 million in Q1 2022 per SLDB's latest filing, down from $8.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $20.7 million in Q4 2020 and bottomed at $6.2 million in Q1 2022.
  • Median Current Deferred Revenue over the past 3 years was $11.6 million (2021), compared with a mean of $12.6 million.
  • The largest annual shift saw Current Deferred Revenue tumbled 61.0% in 2021 before it tumbled 65.07% in 2022.
  • Over 3 years, Current Deferred Revenue stood at $20.7 million in 2020, then crashed by 61.0% to $8.1 million in 2021, then dropped by 23.64% to $6.2 million in 2022.
  • Business Quant data shows Current Deferred Revenue for SLDB at $6.2 million in Q1 2022, $8.1 million in Q4 2021, and $8.9 million in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Solid Biosciences 713.77 Mn 333.09 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 6.17 Mn
Dec 31, 2021 8.08 Mn
Sep 30, 2021 8.87 Mn
Jun 30, 2021 14.35 Mn
Mar 31, 2021 17.66 Mn
Dec 31, 2020 20.72 Mn